Hollow Brook Wealth Management’s Rein Therapeutics RNTX Stock Holding History

Hollow Brook Wealth Management’s Portfolio RNTX Stock Details RNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,250	Closed	-$31K	–	69
2021 Q2	$31K	Hold	1,250	–	–	0.02%	60
2021 Q1	$36K	Hold	1,250	–	–	0.02%	51
2020 Q4	$26K	Hold	1,250	–	–	0.02%	50
2020 Q3	$32K	Hold	1,250	–	–	0.02%	46
2020 Q2	$29K	Hold	1,250	–	–	0.02%	41
2020 Q1	$8K	Hold	1,250	–	–	0.01%	41
2019 Q4	$14K	Hold	1,250	–	–	0.01%	61
2019 Q3	$17K	Hold	1,250	–	–	0.01%	54
2019 Q2	$18K	Hold	1,250	–	–	0.02%	51
2019 Q1	$49K	Sell	1,250 -250	-17%	-$7.79K	0.05%	47
2018 Q4	$25K	Buy	+1,500	New	+$60.3K	0.03%	46

Other funds holding RNTX

AIM

Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AIIC

AJU IB Investment Company Seoul, South Korea $30.5M AUM 128.96% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Hollow Brook Wealth Management's RNTX Position: Q3 2021 in Review

Hollow Brook Wealth Management sold out of Rein Therapeutics (RNTX) in Q3 2021, closing a stake of 1,250 shares — an estimated $31K sold.

Hollow Brook Wealth Management first reported a position in RNTX in Q4 2018 and held it in 11 quarters. The position peaked at $49K in Q1 2019. 43 funds tracked by Wall St. Rank hold RNTX as of Q3 2021.

Hollow Brook Wealth Management reported no remaining Rein Therapeutics position as of Q3 2021 after selling out during the quarter.
Hollow Brook Wealth Management sold 1,250 Rein Therapeutics shares in Q3 2021, an estimated $31K.
Hollow Brook Wealth Management first reported a position in Rein Therapeutics in Q4 2018 and held it in 11 quarters.
Hollow Brook Wealth Management's Rein Therapeutics position peaked at $49K in Q1 2019.
43 funds tracked by Wall St. Rank held Rein Therapeutics as of Q3 2021.

Based on Hollow Brook Wealth Management's 13F filing for Q3 2021, filed 12 Nov 2021.